-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027

Benzinga·10/22/2026 07:46:04
  • Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO
  • Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027